Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | THRA | P10827 | 8/20 | 0.43 |
| ▸ | THRB | P10828 | 8/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4253929 | 1.00 | MAOA (0.45) | MAOAMAOBTHRATHRBPLA2G2A | |
| SCHEMBL4778745 | 0.93 | MAOA (0.41) | MAOAMAOBTHRATHRBPLA2G2A | |
| SCHEMBL4778737 | 0.93 | MAOA (0.41) | MAOAMAOBTHRATHRBPLA2G2A | |
| SCHEMBL4261211 | 0.90 | MAOA (0.47) | MAOAMAOBTHRATHRBPLA2G2A | |
| SCHEMBL4261209 | 0.90 | MAOA (0.47) | MAOAMAOBTHRATHRBPLA2G2A | |
| SCHEMBL24392404 | 0.84 | KDM4E (0.46) | PLA2G2AKDM4EALDH1A1HPGDCYP1A2 | |
| SCHEMBL29589039 | 0.84 | KDM4E (0.46) | PLA2G2AKDM4EALDH1A1HPGDCYP1A2 | |
| SCHEMBL29262921 | 0.84 | KDM4E (0.46) | PLA2G2AKDM4EALDH1A1HPGDCYP1A2 | |
| SCHEMBL14418090 | 0.81 | ALDH1A1 (0.42) | THRATHRBKDM4EALDH1A1HPGD | |
| SCHEMBL24393315 | 0.78 | KDM4E (0.45) | KDM4EALDH1A1HPGDCYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8828991-B2 | Azacyclyl-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments | SANOFI (FR) | 2014-09-09 | — | — | US | disclosed |
| US-20090082339-A1 | NOVEL AZACYCLYL-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082339-A1 | NOVEL AZACYCLYL-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | MCHR1, MPI, TPMT | MAOA 785/4885MAOB 937/4885THRA 1818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.